CureVac N.V. Form 6-K (April 15, 2021)
Summary
A Form 6-K report of foreign private issuer filed by CureVac N.V. with the U.S. Securities and Exchange Commission for the month of April, 2021, Commission File Number 001-39446. It states that on April 15, 2021 the company issued a press release announcing its financial results and business updates for the fourth quarter and full-year of 2020. The report is signed by Franz-Werner Haas, LLD, LLM, Chief Executive Officer, and lists the press release as Exhibit 99.1.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“CureVac N.V. Form 6-K (April 15, 2021).”
Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-cvac-6-k-filed2021-04-15-0001104659-21-050531-f8a70ed93b/
, SHA-256 6a26d89ff66f220fb30336ae3376a128c91a06a2701ae4adb6ccaefc46eb6791.Full text
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of April, 2021 Commission File Number: 001-39446 CureVac N.V. ( Exact Name of Registrant as Specified in Its Charter ) Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: Form 20-F | x | Form 40-F | ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Yes | ¨ | No | x Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): Yes | ¨ | No | x On April 15, 2021, CureVac N.V. (the “Company”) issued a press release announcing the Company’s financial results and business updates for the fourth quarter and full-year of 2020. The information in this Form 6-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CUREVAC N.V. By: | /s/ Franz-Werner Haas, LLD, LLM Chief Executive Officer Date: April 15, 2021 EXHIBIT INDEX EXHIBIT NO. | DESCRIPTION 99.1 | CureVac N.V. Press Release dated April 15, 2021.
File and source
- File
- SEC_CVAC_6-K_filed2021-04-15_0001104659-21-050531.htm
- Size
- 14,250 bytes
- SHA-256
- 6a26d89ff66f220fb30336ae3376a128c91a06a2701ae4adb6ccaefc46eb6791
- Original
- www.sec.gov